Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,786 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.
Bahit MC, Vora AN, Li Z, Wojdyla DM, Thomas L, Goodman SG, Aronson R, Jordan JD, Kolls BJ, Dombrowski KE, Vinereanu D, Halvorsen S, Berwanger O, Windecker S, Mehran R, Granger CB, Alexander JH, Lopes RD. Bahit MC, et al. Among authors: mehran r. JAMA Cardiol. 2022 Jul 1;7(7):682-689. doi: 10.1001/jamacardio.2022.1166. JAMA Cardiol. 2022. PMID: 35612866 Free PMC article. Clinical Trial.
Comparison of clinical outcomes using stents versus no stents after percutaneous coronary intervention for proximal left anterior descending versus proximal right and left circumflex coronary arteries.
Ashby DT, Dangas G, Mehran R, Lansky AJ, Narasimaiah R, Iakovou I, Polena S, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB. Ashby DT, et al. Among authors: mehran r. Am J Cardiol. 2002 May 15;89(10):1162-6. doi: 10.1016/s0002-9149(02)02297-x. Am J Cardiol. 2002. PMID: 12008168
Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial).
Kandzari DE, Tcheng JE, Cohen DJ, Bakhai A, Grines CL, Cox DA, Effron M, Stuckey T, Griffin JJ, Turco M, Carroll JD, Fahy M, Mehran R, Stone GW; CADILLAC Investigators. Kandzari DE, et al. Among authors: mehran r. Am J Cardiol. 2003 Oct 1;92(7):779-84. doi: 10.1016/s0002-9149(03)00882-8. Am J Cardiol. 2003. PMID: 14516875 Clinical Trial.
Comparison of effect of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions on risk of hemorrhagic stroke in patients >or=75 years of age versus those <75 years of age.
Iakovou I, Dangas G, Mehran R, Mintz GS, Lansky AJ, Aymong ED, Nikolsky E, Vagaonescu T, Glasser LA, Stone GW, Leon MB, Moses JW. Iakovou I, et al. Among authors: mehran r. Am J Cardiol. 2003 Nov 1;92(9):1083-6. doi: 10.1016/j.amjcard.2003.07.007. Am J Cardiol. 2003. PMID: 14583360
Comparison of frequency of hemorrhagic stroke in patients <75 years versus > or =75 years of age among patients receiving glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions.
Iakovou I, Dangas G, Mintz GS, Mehran R, Lansky AJ, Aymong ED, Nikolsky E, Vagaonescu T, Glasser LA, Stone GW, Leon MB, Moses JW. Iakovou I, et al. Among authors: mehran r. Am J Cardiol. 2004 Feb 1;93(3):346-9. doi: 10.1016/j.amjcard.2003.10.018. Am J Cardiol. 2004. PMID: 14759388
Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC trial).
Halkin A, Aymong E, Cox DA, Mehran R, Lansky AJ, Fahy M, Weisz G, Garcia E, Tcheng JE, Grines CL, Stone GW. Halkin A, et al. Among authors: mehran r. Am J Cardiol. 2004 Feb 1;93(3):349-53. doi: 10.1016/j.amjcard.2003.10.019. Am J Cardiol. 2004. PMID: 14759389
1,786 results